文献速递骨软组织肉瘤与黑色素瘤

皮肤黑色素瘤前哨淋巴结阳性判读不一致率高:专家复核可减少不必要的辅助治疗

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment.
PubMed 文献 · Eur J Cancer · 2021-04-10

该研究从荷兰病理登记库选取2003–2014年接受前哨淋巴结活检的黑色素瘤患者,对阳性切片进行专家复核。322例复核患者中38例(11.8%)由转移降级为淋巴结痣,至少4.3%患者可能被错误纳入辅助治疗;降级患者5年无复发生存率与真阴性者相似。作者建议考虑辅助治疗时应由黑色素瘤专家病理医师复核前哨淋巴结活检。

要点

  • 前哨淋巴结阳性判读中11.8%被降级为淋巴结痣。
  • 至少4.3%患者可能因误判而错误接受辅助治疗。
  • 低肿瘤负荷和包膜下位置与误判风险升高相关。

核心结论

  • 超过10%的初判前哨淋巴结阳性黑色素瘤活检实为误判的淋巴结痣。
  • 考虑辅助治疗时,前哨淋巴结活检应由黑色素瘤专家病理医师复核。

研究设计与样本

  • 从荷兰病理登记库(PALGA)选取2003–2014年接受前哨淋巴结活检的黑色素瘤患者。
  • 调取前哨淋巴结阳性患者的组织病理切片供复核,由专家黑色素瘤病理医师随机抽样重新评估。
  • 比较误判(假阳性)患者与真阳性患者的无复发生存率,并纳入前哨淋巴结阴性组作对照。
  • 采用多因素logistic分析评估与误判相关的临床病理特征。

主要发现

  • 322例复核患者中38例(11.8%)诊断由黑色素瘤转移降级为淋巴结痣。
  • 按III期辅助治疗试验纳入标准,至少4.3%患者可能被错误判定符合辅助治疗条件。
  • 多因素分析显示前哨淋巴结肿瘤负荷低和包膜下肿瘤位置的患者被误判几率显著更高。
  • 38例降级患者5年无复发生存率为86.7%(95%CI 72.6–96.6),与6413例前哨淋巴结阴性患者的85.9%(95%CI 84.9–86.8,p=0.18)相似。
  • 降级患者5年无复发生存率优于284例复核后真阳性患者的53.2%(95%CI 47.2–59.9,p=0.009)。

临床怎么用

  • 对III期黑色素瘤患者考虑辅助治疗前,应将前哨淋巴结活检切片交由黑色素瘤专家病理医师复核。
  • 低肿瘤负荷或包膜下位置的前哨淋巴结阳性结果应特别警惕误判可能。

局限性

  • 研究基于荷兰病理登记库的回顾性样本,专家复核仅针对随机抽样部分。
  • 误判相关因素为多因素分析结果,未报告具体效应量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Identification of sentinel node (SN) metastases can set the adjuvant systemic therapy indication for patients with stage III melanoma. Studies re-evaluating the diagnosis of initially positive SN biopsies are scarce. MATERIALS AND METHODS: Dutch patients with melanoma who underwent SN biopsy between 2003 and 2014 were selected from PALGA, the Dutch Pathology Registry. Histopathological slides of SN-positive patients were retrieved for review. A random sample was reassessed by an expert melanoma pathologist. Recurrence-free survival (RFS) of patients who were misclassified (false-positive) was compared with those with a true positive SN status. For comparison, a group of SN-negative patients was included. Multivariable logistic analysis was performed to assess clinicopathological characteristics associated with misclassification of SN status. RESULTS: Diagnosis was downgraded from melanoma metastasis to nodal nevus in 38 of the 322 reviewed patients (11.8%). Considering the inclusion criteria of phase III adjuvant trials, at least 4.3% of patients would have falsely qualified for adjuvant therapy. In multivariable analysis, patients with a low SN tumour burden and subcapsular SN tumour location had a significantly higher chance of being misclassified. The five-year RFS of the 38 downgraded patients was 86.7% (95% confidence interval [CI] = 72.6-96.6), similar to the 85.9% (95% CI = 84.9-86.8, p = 0.18) for 6413 SN-negative patients and better than the 53.2% (95% CI = 47.2-59.9, p = 0.009) of 284 patients who were truly SN positive upon review. CONCLUSION: More than 10% of originally positive SN biopsies of patients with melanoma concern misclassified nodal nevi. We advocate that when adjuvant treatment is considered in patients with stage III melanoma, SN biopsies should be reassessed by an expert melanoma pathologist.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. El Sharouni MA, Laeijendecker AE, Suijkerbuijk KP, et al. High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. Eur J Cancer. 2021. PMID: 33848712. doi:10.1016/j.ejca.2021.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。